• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Zura Bio Limited

    11/14/24 4:47:14 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ZURA alert in real time by email
    SC 13G 1 tm2428381d4_sc13g.htm SC 13G

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.)*

     

    ZURA BIO LIMITED

    (Name of Issuer)

     

    Class A Ordinary Shares, par value $0.0001 per share

    (Title of Class of Securities)

     

    G9TY5A101

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. G9TY5A101

     

    1 Names of reporting persons
    ADAR1 Capital Management, LLC
    2 Check the appropriate box if a member of a group (see instructions)
    (a) ¨
    (b) 
    x
    3 SEC use only
     
    4 Citizenship or place of organization   
    Texas

    Number of
    shares
    beneficially
    owned by each
    reporting
    person with:
    5 Sole voting power
    0
    6 Shared voting power

    3,332,835(1)

    7 Sole dispositive power
    0
    8 Shared dispositive power
    3,332,835(1)

    9 Aggregate amount beneficially owned by each reporting person
    3,332,835
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ¨
    11 Percent of class represented by amount in Row (9)
    5.10%(2)
    12 Type of reporting person (see instructions)
    OO 

     

    (1) Includes (i) 2,959,155 Class A ordinary shares, par value $0.0001 per share (“Class A Ordinary Shares”) held by ADAR1 Partners, LP, and (ii) 373,680 shares of Class A Ordinary Shares held by Spearhead Insurance Solutions IDF, LLC as of November 5, 2024. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC.
    (2) Based on 65,293,530 shares of Class A Ordinary Shares of ZURA BIO LIMITED (the “Issuer”) outstanding as of November 4, 2024 reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, filed with the SEC on November 7, 2024.

     

    2 

     

     

    CUSIP No. G9TY5A101

     

    1 Names of reporting persons
    ADAR1 Capital Management GP, LLC
    2 Check the appropriate box if a member of a group (see instructions)
    (a) ¨
    (b) 
    x
    3 SEC use only
     
    4 Citizenship or place of organization
    Texas

    Number of
    shares
    beneficially
    owned by each reporting
    person with:
    5 Sole voting power
    0
    6 Shared voting power
    2,959,155(1)
    7 Sole dispositive power
    0
    8 Shared dispositive power
    2,959,155(1)

    9 Aggregate amount beneficially owned by each reporting person
    2,959,155
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ¨
    11 Percent of class represented by amount in Row (9)
    4.53%(2)
    12 Type of reporting person (see instructions)
    OO

     

    (1) Includes 2,959,155 shares of Class A Ordinary Shares directly held by ADAR1 Partners, LP as of November 5, 2024. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP.
    (2) Based on 65,293,530 shares of Class A Ordinary Shares of the Issuer outstanding as of November 4, 2024 reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, filed with the SEC on November 7, 2024.

     

    3 

     

     

    CUSIP No. G9TY5A101

     

    1 Names of reporting persons
    Daniel Schneeberger
    2 Check the appropriate box if a member of a group (see instructions)
    (a) ¨
    (b) 
    x
    3 SEC use only
     
    4 Citizenship or place of organization
    Switzerland

    Number of
    shares
    beneficially
    owned by each reporting
    person with:
    5 Sole voting power
    0
    6 Shared voting power
    3,332,835(1)
    7 Sole dispositive power
    0
    8 Shared dispositive power
    3,332,835(1)

    9 Aggregate amount beneficially owned by each reporting person
    3,332,835
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ¨
    11 Percent of class represented by amount in Row (9)
    5.10%(2)
    12 Type of reporting person (see instructions)
    IN

     

    (1) Includes (i) 2,959,155 shares of Class A Ordinary Shares held by ADAR1 Partners, LP, and (ii) 373,680 shares of Class A Ordinary Shares held by Spearhead Insurance Solutions IDF, LLC as of November 5, 2024. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC.
    (2) Based on 65,293,530 shares of Class A Ordinary Shares of the Issuer outstanding as of November 4, 2024 reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, filed with the SEC on November 7, 2024.

     

    4 

     

     

    Item 1(a) Name of issuer:

     

    ZURA BIO LIMITED

     

    Item 1(b) Address of issuer’s principal executive offices:

     

    1489 W. Warm Springs Rd. #110, Henderson, NV 89014

     

    Item 2(a) Name of person filing:

     

    This Schedule is being filed on behalf of each of the following persons (each, a “Reporting Person” and collectively, the “Reporting Persons”):

     

      (i) ADAR1 Capital Management, LLC (“ADAR1 Capital Management”);
      (ii) ADAR1 Capital Management GP, LLC (“ADAR1 General Partner”); and
      (iii) Daniel Schneeberger (“Mr. Schneeberger”).

     

    Item 2(b) Address or principal business office or, if none, residence:

     

    The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738.

     

    Item 2(c) Citizenship:

     

      (i) ADAR1 Capital Management is a Texas limited liability company;
      (ii) ADAR1 General Partner is a Texas limited liability company; and
      (iii) Mr. Schneeberger is a citizen of Switzerland.

     

    Item 2(d) Title of Class of Securities:

     

    Class A Ordinary Shares, par value $0.0001 per share

     

    Item 2(e) CUSIP No.:

     

    G9TY5A101

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
         
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
         
      (c) ¨ Insurance company defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
         
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); 
         
      (e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); 

     

    5 

     

     

      (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); 
         
      (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); 
         
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); 
         
      (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); 
         
      (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). 

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ______________.

     

    Item 4. Ownership

     

    ADAR1 Capital Management, LLC  

     

    Amount beneficially owned:   3,332,835 
    Percent of class:   5.10%
    Number of shares as to which the Reporting Person has:     
    Sole power to vote or direct the vote:   0 
    Shared power to vote or direct the vote:   3,332,835 
    Sole power to dispose or direct the disposition of:   0 
    Shared power to dispose or direct the disposition of:   3,332,835 

     

    ADAR1 Capital Management GP, LLC  

     

    Amount beneficially owned:   2,959,155 
    Percent of class:   4.53%
    Number of shares as to which the Reporting Person has:     
    Sole power to vote or direct the vote:   0 
    Shared power to vote or direct the vote:   2,959,155 
    Sole power to dispose or direct the disposition of:   0 
    Shared power to dispose or direct the disposition of:   2,959,155 

     

    Daniel Schneeberger  

     

    Amount beneficially owned:   3,332,835 
    Percent of class:   5.10%
    Number of shares as to which the Reporting Person has:     
    Sole power to vote or direct the vote:   0 
    Shared power to vote or direct the vote:   3,332,835 
    Sole power to dispose or direct the disposition of:   0 
    Shared power to dispose or direct the disposition of:   3,332,835 

     

    6 

     

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    7 

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 14, 2024

     

      ADAR1 CAPITAL MANAGEMENT, LLC
       
      /s/ Daniel Schneeberger 
      Daniel Schneeberger 
      Manager
       
      ADAR1 CAPITAL MANAGEMENT GP, LLC
       
      /s/ Daniel Schneeberger 
      Daniel Schneeberger 
      Manager
       
      /s/ Daniel Schneeberger 
      Daniel Schneeberger, in his individual capacity

     

    8 

     

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to Class A ordinary shares, par value $0.0001 per share of ZURA BIO LIMITED, a Cayman Islands corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings.

     

    In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement as of November 14, 2024.

     

      ADAR1 CAPITAL MANAGEMENT, LLC
       
      /s/ Daniel Schneeberger 
      Daniel Schneeberger 
      Manager
       
      ADAR1 CAPITAL MANAGEMENT GP, LLC
       
      /s/ Daniel Schneeberger 
      Daniel Schneeberger 
      Manager
       
      /s/ Daniel Schneeberger 
      Daniel Schneeberger, in his individual capacity

     

    9 

     

    Get the next $ZURA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZURA

    DatePrice TargetRatingAnalyst
    2/9/2026$15.00Outperform
    Wedbush
    11/4/2024$15.00Outperform
    Leerink Partners
    9/5/2024$5.00Neutral
    H.C. Wainwright
    5/3/2024$26.00Overweight
    Piper Sandler
    10/10/2023$10.00Buy
    Ladenburg Thalmann
    8/25/2023$17.00Outperform
    Oppenheimer
    6/22/2023$20.00Buy
    Guggenheim
    6/14/2023$14.00Buy
    Chardan Capital Markets
    More analyst ratings

    $ZURA
    SEC Filings

    View All

    Zura Bio Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Zura Bio Ltd (0001855644) (Filer)

    3/5/26 7:00:42 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: Zura Bio Limited filed SEC Form 8-K: Financial Statements and Exhibits

    8-K/A - Zura Bio Ltd (0001855644) (Filer)

    2/26/26 8:42:51 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by Zura Bio Limited

    424B5 - Zura Bio Ltd (0001855644) (Filer)

    2/25/26 5:06:18 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ZURA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress

    Zura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that the design of its ongoing Phase 2 TibuSURE clinical trial evaluating tibulizumab (ZB-106) in systemic sclerosis (SSc) has been accepted for poster presentation at the Systemic Sclerosis World Congress, taking place March 5–7, 2026 in Athens, Greece. The poster, titled "TibuSURE: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of

    3/5/26 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zura Bio to Participate in Upcoming Investor Conferences

    Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that members of its management team will participate in the following upcoming investor conferences: Leerink Global Healthcare Conference Location: Miami, FL Fireside chat: Tuesday, March 10, 2026, at 2:20 p.m. ET Investor meetings: Management will meet with investors Jefferies Biotech on the Beach Summit Location: Miami, FL Date: Wednesday, March 11, 2026 Investor meetings: Management will meet with

    3/2/26 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

    Zura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that it closed its previously announced underwritten public offering of Class A ordinary shares and pre‑funded warrants on February 26, 2026. The offering consisted of 21,200,000 Class A ordinary shares priced at $6.25 per share, along with pre‑funded warrants for 1,800,000 Class A ordinary shares priced at $6.249 per warrant, which included 3,000,000 additional Class A ordinary shares sold upon exercise in full by the underwriters of th

    2/27/26 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ZURA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ai Biotechnology Llc bought $12,500,000 worth of Class A Ordinary Shares (2,000,000 units at $6.25) (SEC Form 4)

    4 - Zura Bio Ltd (0001855644) (Issuer)

    3/2/26 5:55:03 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ploos Van Amstel Arnout bought $496,000 worth of Class A ordinary shares (80,000 units at $6.20), increasing direct ownership by 400% to 100,000 units (SEC Form 4)

    4 - Zura Bio Ltd (0001855644) (Issuer)

    5/23/24 8:53:36 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Howell Michael bought $24,999 worth of Class A ordinary shares (7,987 units at $3.13) (SEC Form 4)

    4 - Zura Bio Ltd (0001855644) (Issuer)

    4/24/24 6:54:25 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ZURA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush initiated coverage on Zura Bio Limited with a new price target

    Wedbush initiated coverage of Zura Bio Limited with a rating of Outperform and set a new price target of $15.00

    2/9/26 6:54:14 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Leerink Partners initiated coverage on Zura Bio Limited with a new price target

    Leerink Partners initiated coverage of Zura Bio Limited with a rating of Outperform and set a new price target of $15.00

    11/4/24 7:45:03 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Zura Bio Limited with a new price target

    H.C. Wainwright initiated coverage of Zura Bio Limited with a rating of Neutral and set a new price target of $5.00

    9/5/24 8:35:06 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ZURA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Nirula Ajay

    4 - Zura Bio Ltd (0001855644) (Issuer)

    3/5/26 6:30:17 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Nirula Ajay

    3 - Zura Bio Ltd (0001855644) (Issuer)

    3/5/26 6:29:24 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Ai Biotechnology Llc bought $12,500,000 worth of Class A Ordinary Shares (2,000,000 units at $6.25) (SEC Form 4)

    4 - Zura Bio Ltd (0001855644) (Issuer)

    3/2/26 5:55:03 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ZURA
    Leadership Updates

    Live Leadership Updates

    View All

    Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors

    Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointments of Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors, effective February 21, 2026. As part of this transition, Neil Graham, M.B.B.S., M.D., M.P.H., will step down from the Board effective the same date. "Mark and Ajay are accomplished immunology executives who have successfully guided innovative biologics from early development through approval and commercialization on a

    2/23/26 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer

    Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointment of Sandeep Kulkarni, M.D. as Chief Executive Officer (CEO), effective January 21, 2026. Dr. Kulkarni will also continue serving as a Director of Zura. Dr. Kulkarni succeeds Kim Davis, J.D., who has served as Interim CEO since October 2025 following the commencement of a medical leave of absence by CEO Robert Lisicki. Mr. Lisicki is resigning as CEO and as a Director, effective as of January 21, 2026. Ms.

    1/21/26 8:50:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zura Bio Announces Chief Financial Officer Transition

    Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 7, 2025. He will succeed Verender Badial, who will step down from the role and remain with the company as a non-executive employee through July 31, 2025, to support a seamless transition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701021645/en/Eric Hyllengren Mr. Badial joined Zura Bio in March 2023, at the time of its business combination with

    7/1/25 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ZURA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

    SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 5:52:59 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

    SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 5:06:21 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Zura Bio Limited

    SC 13G - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 4:47:14 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ZURA
    Financials

    Live finance-specific insights

    View All

    Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

    Achieved key milestones in 2024 that enhanced our leadership team, strengthened our financial position, and progressed our clinical pipeline Initiated the Phase 2 TibuSURE trial in adults with systemic sclerosis (SSc) Completed a $112.5 million private placement financing in April 2024, contributing to a total of $176.5 million in cash and cash equivalents, as of December 31, 2024 Cash runway anticipated through 2027, supporting operations and funding anticipated tibulizumab data readouts in SSc and hidradenitis suppurativa (HS) Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for

    3/25/25 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

    Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa (HS) in Q2 2025 Cash, cash equivalents and investments totaling $188.2 million as of September 30, 2024, are anticipated to support operations, as currently planned, through 2027 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter of 2024 and recent corporate updates. "In the third quarter of 2024, we made significant progress toward initiating our first Phase 2 tria

    11/7/24 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights

    Initiating Phase 2 clinical trials in 2024 to evaluate ZB-106 (tibulizumab) in systemic sclerosis and hidradenitis suppurativa, and ZB-168 in alopecia areata Experienced team building the next Immunology leader Cash position of $103.9 million in cash, cash equivalents and investments is expected to support development and operations into 2026 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio") a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights. "In the third quarter, Zura Bio made significant progress

    11/13/23 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care